Ring finger protein 43 gene and cancer

doi:10.3760/cma.j.issn.1673-422X.2016.01.006

Abstract

Abstract: Ring finger protein 43 (RNF43) gene is closely associated with the development of various types of human tumors. The mainly mechanisms of RNF43 gene are mutation and aberrant expression. Activated RNF43 protein participates in the proliferation, apoptosis, metastasis through some signal pathways and influences the tumorigenesis and development in colorectal cancer, hepatocellular carcinoma, which plays a role of oncogene. However, it is considered as a tumor suppressor gene in mucinous ovarian tumors and intraductal papillary mucinous neoplasms of the pancreas.

Key words: Neoplasms, Ring finger protein 43 gene

Wang Shixiong, Li Yaoping. Ring finger protein 43 gene and cancer[J]. Journal of International Oncology, 2016, 43(1): 23-25.

References

［1］ Yagyu R, Furukawa Y, Lin YM, et al. A novel oncoprotein RNF43 functions in an autocrine manner in colorectal cancer［J］. Int J Oncol, 2004, 25(5): 1343-1348. ［2］ Sugiura T, Yamaguchi A, Miyamoto K. A cancerassociated RING finger protein, RNF43, is a ubiquitin ligase that interacts with a nuclear protein, HAP95［J］. Exp Cell Res, 2008, 314(7): 15191528. DOI:10.1016/j.yexcr.2008.01.013. ［3］ Jackson PK, Eldridge AG, Freed E, et al. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases［J］. Trends Cell Biol, 2000, 10(10): 429-439. ［4］ Ahel I, Ahel D, Matsusaka T, et al. Poly(ADPribose)binding Zinc finger motifs in DNA repair/checkpoint proteins［J］. Nature, 2008, 451(7174): 81-85. DOI:10.1038/nature06420. ［5］ Nillegoda NB, Theodoraki MA, Mandal AK, et al. Ubr1 and Ubr2 function in a quality control pathway for degradation of unfolded cytosolic proteins［J］. Mol Biol Cell, 2010, 21(13): 2102-2116. DOI:10.1091/mbc.E10020098. ［6］ Shinada K, Tsukiyama T, Sho T, et al. RNF43 interacts with NEDL1 and regulates p53mediated transcription［J］. Biochem Biophys Res Commun, 2011, 404(1): 143-147. DOI:10.1016/j.bbrc.2010.11.082. ［7］ Li Y, Ozaki T, Kikuchi H, et al. A novel HECTtype E3 ubiquitin protein ligase NEDL1 enhances the p53mediated apoptotic cell death in its catalytic activityindependent manner［J］. Oncogene, 2008, 27(26): 3700-3709. DOI:10.1038/sj.onc.1211032. ［8］ Miyamoto K, Sakurai H, Sugiura T. Proteomic identification of a PSF/p54nrb heterodimer as RNF43 oncoproteininteracting proteins［J］. Proteomics, 2008, 8(14): 2907-2910. DOI:10.1002/pmic.200800083. ［9］ Koo BK, Spit M, Jordens I, et al. Tumour suppressor RNF43 is a stemcell E3 ligase that induces endocytosis of Wnt receptors［J］. Nature, 2012, 488(7413): 665-669. DOI:10.1038/nature11308. ［10］ Takahashi N, Yamaguchi K, Ikenoue T, et al. Identification of two Wntresponsive elements in the intron of RING finger protein 43 (RNF43) gene［J］. PLoS One, 2014, 9(1): e86582. DOI:10.1371/journal.pone.0086582. ［11］ Jiang X, Hao HX, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma［J］. Proc Natl Acad Sci USA, 2013, 110(31): 12649-12654. DOI:10.1073/pnas.1307218110. ［12］ Zou Y, Wang F, Liu FY, et al. RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer［J］. Gene, 2013, 531(1): 112116. DOI:10.1016/j.gene.2013.08.054. ［13］ Ryland GL, Hunter SM, Doyle MA, et al. RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary［J］. J Pathol, 2013, 229(3): 469-476. DOI:10.1002/path.4134. ［14］ Sakamoto H, Kuboki Y, Hatori T, et al. Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas［J］. Mod Pathol, 2015, 28(2): 261-267. DOI:10.1038/modpathol.2014.98. ［15］ Giannakis M, Hodis E, Jasmine Mu X, et al. RNF43 is frequently mutated in colorectal and endometrial cancers［J］. Nat Genet, 2014, 46(12): 1264-1266. DOI:10.1038/ng.3127. ［16］ Uchida N, Tsunoda T, Wada S, et al. Ring finger protein 43 as a new target for cancer immunotherapy［J］. Clin Cancer Res, 2004, 10(24): 8577-8586. DOI:10.1158/10780432.CCR040104. ［17］ Xing C, Zhou W, Ding S, et al. Reversing effect of ring finger protein 43 inhibition on malignant phenotypes of human hepatocellular carcinoma［J］. Mol Cancer Ther, 2013, 12(1): 94-103. DOI:10.1158/15357163.MCT120672. ［18］ Amato E, Molin MD, Mafficini A, et al. Targeted nextgeneration sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas［J］. J Pathol, 2014, 233(3): 217-227. DOI:10.1002/path.4344.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.